AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment derived from the C-terminal domain of human growth hormone (hGH), specifically amino acids 176–191, with a stabilizing tyrosine residue at the N-terminus. The peptide was originally synthesized to isolate the lipolytic signaling domain of hGH while excluding the broader anabolic and IGF-1-associated effects of the full-length hormone. In preclinical experimental models, AOD-9604 has been investigated for its interaction with beta-3 adrenergic receptor pathways in adipose tissue. Published rodent studies report observations related to fat oxidation, lipogenesis inhibition, and adipocyte-specific metabolic signaling. Notably, experimental data suggest that AOD-9604 does not modulate IGF-1 levels or glucose metabolism in the systems studied. Additional preclinical research has examined AOD-9604 in cartilage and bone remodeling models. In-vitro studies report increased proteoglycan and collagen production in chondrocyte cultures following peptide exposure, supporting its use as a molecular probe for investigating extracellular matrix dynamics. Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂ Molecular Weight: 1815.10 g/mol CAS: 221231-10-3 This product is supplied exclusively for laboratory research use. Not for human consumption.